Category: 859518-35-7

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.859518-35-7,tert-Butyl 3-cyanopiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.,859518-35-7

To a solution of tert-butyl 3-cyanopiperazine-1-carboxylate (21.1 g, 0.1 mol) and aqueous formaldehyde (24 g, 37% in water) in THF was added sodium cyanoborohydride (31.5 g, 0.5 mol) in small portions. The reaction mixture was aged at ambient temperature overnight then diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by column chromatography to provide the title compound. 1H NMR (400 MHz, MeOD) delta 4.23-4.18 (m, 1H), 4.01-3.97 (br, 1H), 3.92-3.90 (br, 1H), 2.92-2.89 (br, 1H), 2.88-2.87 (br, 1H), 2.65-2.62 (m, 1H), 2.378 (s, 3H), 2.36-2.33 (m, 1H), 1.47 (s, 9H).

As the paragraph descriping shows that 859518-35-7 is playing an increasingly important role.

Reference：
Patent; JANSSEN PHARMACEUTICA NV; ORTHO-CLINICAL DIAGNOSTICS, INC; DONAHUE, Matthew Garrett; GONG, Yong; SALTER, Rhys; HRYHORENKO, Eric; DECORY, Thomas R.; REMMERIE, Bart M.; SANKARAN, Banumathi; WO2014/31587; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

859518-35-7, tert-Butyl 3-cyanopiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 39 Piperazine-2-carbonitrile To a mixture of tert-butyl 3-cyanopiperazine-1-carboxylate (200 mg, 0.95 mmol) in dichloromethane (10 mL), CF3COOH (2 mL) was added and the resulting was stirred at RT for 1 h. The mixture was concentrated in vacuo to afford the crude product., 859518-35-7

The synthetic route of 859518-35-7 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Ren, Pingda; Liu, Yi; Li, Liansheng; Feng, Jun; Wu, Tao; US2014/288045; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.859518-35-7,tert-Butyl 3-cyanopiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.,859518-35-7

To a mixture of tert-butyl 3 -cyanopiperazine- 1 -carboxylate (200 mg, 0.95 mmol) in dichioromethane (10 mL), CF3COOH (2 mL) was added and theresulting was stirred at RT for 1 h. The mixture was concentrated in vacuo to afford the crude product.

859518-35-7 tert-Butyl 3-cyanopiperazine-1-carboxylate 53487922, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; ARAXES PHARMA LLC; JANES, Matthew, Robert; PATRICELLI, Matthew, Peter; LI, Liansheng; REN, Pingda; LIU, Yi; (397 pag.)WO2016/44772; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

859518-35-7, tert-Butyl 3-cyanopiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,859518-35-7

To a solution of ten-butyl 3-cyanopiperazine-1-carboxylate (21.1 g, 0.1mol) and aqueous formaldehyde (24 g. 37% in water) in THF was added sodiumcyanoborohydride (315 g, 0.5 rnol) in small portions. The reaction mixture was agedat ambient temperature overnight then diluted with water and extracted with ethylacetate. The organic phase was washed with saturated aqueous sodium chloride,dried over anhydrous sodium sulfate. filtered, and concentrated under vacuum. Thecrude product was purified by column chromatography to provide the title compound.1H NMR (400MHz, MeOD) o 4.23-4.18 (m, 1H), 4.01-3.97 (br, 1H), 3.92-3.90 (br,1 H), 2.92-2.89 (br, 1 H). 2.88-2.87 (br, 1 H), 2.65-2.62 (m, 1 H), 2.378 (s, 3H), 2.36-2.33 (m, 1H), 1.47 (s, 9H).

859518-35-7 tert-Butyl 3-cyanopiperazine-1-carboxylate 53487922, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; ORTHO-CLINICAL DIAGNOSTICS, INC; JANSSEN PHARMACEUTICA NV; HRYHORENKO, Eric; SANKARAN, Banumathi; DECORY, Thomas, R.; TUBBS, Theresa; COLT, Linda; REMMERIE, Bart, M.; SALTER, Rhys; DONAHUE, Matthew, Garrett; GONG, Yong; WO2014/31656; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

859518-35-7, tert-Butyl 3-cyanopiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

859518-35-7, A solution of tert-butyl 3-cyanopiperazine-1-carboxylate, prepared as described in the previous step, (10 g, 0.047 mol) and 2-(2-hydroxyethoxy)acetaldehyde (14.8 g) (see: Bodin, A.,Contact Dermatitis, 2001,44:207) in dichloromethane was treated with formic acid (12.7 g), and the reaction mixture was stirred at room temperature overnight. Sodium cyanoborohydride (7.2 g, 0.118mol) was added in portions. The reaction mixture was stirred at room temperature for 3 hours followed by the addition of water and extraction with dichloromethane. The organic layer was w·ashed with brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to provide the product. 1H NMR: (CDCl3, 400 MHz): delta (ppm) 4.15 (s, 1H), 3.69-3.63 (m, 4H), 3.58 (d, J=4.4 Hz, 2H), 3.47-3.44 (m, 4H), 2.61 (d, J=5.2 Hz, 2H), 2.51-2.48 (m, 4H), 1.43 (s, 9H).

As the paragraph descriping shows that 859518-35-7 is playing an increasingly important role.

Reference：
Patent; JANSSEN PHARMACEUTICA NV; ORTHO-CLINICAL DIAGNOSTICS, INC; DONAHUE, Matthew Garrett; GONG, Yong; SALTER, Rhys; HRYHORENKO, Eric; DECORY, Thomas R.; REMMERIE, Bart M.; SANKARAN, Banumathi; WO2014/31600; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

859518-35-7, tert-Butyl 3-cyanopiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

859518-35-7, A solution of tert-butyl 3-cyanopiperazine-1-carboxylate, prepared as described in the previous step, (10 g, 0.047 mol) and 2-(2-hydroxyethoxy)acetaldehyde (14.8 g) (see: Bodin, A.,Contact Dermatitis, 2001,44:207) in dichloromethane was treated with formic acid (12.7 g), and the reaction mixture was stirred at room temperature overnight. Sodium cyanoborohydride (7.2 g, 0.118mol) was added in portions. The reaction mixture was stirred at room temperature for 3 hours followed by the addition of water and extraction with dichloromethane. The organic layer was w·ashed with brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to provide the product. 1H NMR: (CDCl3, 400 MHz): delta (ppm) 4.15 (s, 1H), 3.69-3.63 (m, 4H), 3.58 (d, J=4.4 Hz, 2H), 3.47-3.44 (m, 4H), 2.61 (d, J=5.2 Hz, 2H), 2.51-2.48 (m, 4H), 1.43 (s, 9H).

As the paragraph descriping shows that 859518-35-7 is playing an increasingly important role.

Reference：
Patent; JANSSEN PHARMACEUTICA NV; ORTHO-CLINICAL DIAGNOSTICS, INC; DONAHUE, Matthew Garrett; GONG, Yong; SALTER, Rhys; HRYHORENKO, Eric; DECORY, Thomas R.; REMMERIE, Bart M.; SANKARAN, Banumathi; WO2014/31600; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.859518-35-7,tert-Butyl 3-cyanopiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

859518-35-7, A solution of tert-butyl 3-cyanopiperazine-1-carboxylate, prepared as described in the previous step, (10 g, 0.047 mol) and 2-(2-hydroxyethoxy)acetaldehyde (14.8 g) (see: Bodin, A., Contact Dermatitis, 2001, 44:207) in dichloromethane was treated with formic acid (12.7 g), and the reaction mixture was stirred at room temperature overnight. Sodium cyanoborohydride (7.2 g, 0.118 mol) was added in portions. The reaction mixture was stirred at room temperature for 3 hours followed by the addition of water and extraction with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to provide the product. 1H NMR: (CDCl3, 400 MHz): delta (ppm) 4.15 (s, 1H), 3.69-3.63 (m, 4H), 3.58 (d, J=4.4 Hz, 2H), 3.47-3.44 (m, 4H), 2.61 (d, J=5.2 Hz, 2H), 2.51-2.48 (m, 4H), 1.43 (s, 9H).

The synthetic route of 859518-35-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Janssen Pharmaceutica NV; Hryhorenko, Eric; Sankaran, Banumathi; DeCory, Thomas R.; Tubbs, Theresa; Colt, Linda; Remmerie, Bart M.; Salter, Rhys; Donahue, Matthew Garrett; Gong, Yong; (53 pag.)US9850318; (2017); B2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.859518-35-7,tert-Butyl 3-cyanopiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.,859518-35-7

To a solution of tert-butyl 3-cyanopiperazine-1-carboxylate (21.1 g, 0.1 mol) and aqueous formaldehyde (24 g, 37% in water) in THF was added sodium cyanoborohydride (31.5 g, 0.5 mol) in small portions. The reaction mixture was aged at ambient temperature overnight then diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by column chromatography to provide the title compound. 1H NMR (400 MHz, MeOD) delta 4.23-4.18 (m, 1H), 4.01-3.97 (br, 1H), 3.92-3.90 (br, 1H), 2.92-2.89 (br, 1H), 2.88-2.87 (br, 1H), 2.65-2.62 (m, 1H), 2.378 (s, 3H), 2.36-2.33 (m, 1H), 1.47 (s, 9H).

As the paragraph descriping shows that 859518-35-7 is playing an increasingly important role.

Reference£º
Patent; JANSSEN PHARMACEUTICA NV; ORTHO-CLINICAL DIAGNOSTICS, INC; DONAHUE, Matthew Garrett; GONG, Yong; SALTER, Rhys; HRYHORENKO, Eric; DECORY, Thomas R.; REMMERIE, Bart M.; SANKARAN, Banumathi; WO2014/31587; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.859518-35-7,tert-Butyl 3-cyanopiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

859518-35-7, Step C tert-Butyl 3-cyano-4-(2-(2-hydroxyethoxy)ethyl)piperazine-1-carboxylate A solution of tert-butyl 3-cyanopiperazine-1-carboxylate, prepared as described in the previous step, (10 g, 0.047 mol) and 2-(2-hydroxyethoxy)acetaldehyde (14.8 g) (see: Bodin, A., Contact Dermatitis, 2001, 44:207) in dichloromethane was treated with formic acid (12.7 g), and the reaction mixture was stirred at room temperature overnight. Sodium cyanoborohydride (7.2 g, 0.118 mol) was added in portions. The reaction mixture was stirred at room temperature for 3 hours followed by the addition of water and extraction with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to provide the product. 1H NMR: (CDCl3, 400 MHz): delta (ppm) 4.15 (s, 1H), 3.69-3.63 (m, 4H), 3.58 (d, J=4.4 Hz, 2H), 3.47-3.44 (m, 4H), 2.61 (d, J=5.2 Hz, 2H), 2.51-2.48 (m, 4H), 1.43 (s, 9H).

859518-35-7 tert-Butyl 3-cyanopiperazine-1-carboxylate 53487922, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Hryhorenko, Eric; Sankaran, Banumathi; DeCory, Thomas R.; Tubbs, Theresa; Colt, Linda; Remmerie, Bart M.; Salter, Rhys; Donahue, Matthew Garrett; Gong, Yong; US2014/57305; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

859518-35-7, tert-Butyl 3-cyanopiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

859518-35-7, To a mixture of 4?,6-dichloro-4-methoxy-[ 1,1 ?-biphenyl] -3 -carboxylic acid (309 mg, 1.04 mmol), EDCI (272 mg, 1.43 mmol), HOBt (195 mg, 1.43 mmol), Et3N (288 mg, 2.85 mmol) in dichloromethane (10 mL) at 0C, piperazine-2-carbonitrile was added at 0C and the resulting mixture was stirred at RT for 8 h. Themixture was partitioned between dichloromethane and water. The organic layer was washed brine, dried over Mg504, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (dichloromethane/methanol = 50:1) to afford the desired product (225 mg, 61% yield). ESI-MS mlz: 444.3 [M+H].

As the paragraph descriping shows that 859518-35-7 is playing an increasingly important role.

Reference£º
Patent; ARAXES PHARMA LLC; JANES, Matthew, Robert; PATRICELLI, Matthew, Peter; LI, Liansheng; REN, Pingda; LIU, Yi; (397 pag.)WO2016/44772; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics